Synopsis
Synopsis
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
NDC API
0
VMF
0
Listed Suppliers
0
API
0
FDF
0
FDF Dossiers
0
FDA Orange Book
0
Europe
0
Canada
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
EDQM
0
USP
0
JP
0
Others
0
US Patents
0
US Exclusivities
0
Health Canada Patents
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
0
News #PharmaBuzz
US Medicaid
NA
Annual Reports
NA
Finished Drug Prices
NA
1. 198414-30-1
2. Telapristone [inn]
3. 65703mv349
4. (8s,11r,13s,14s,17r)-11-(4-(dimethylamino)phenyl)-17-hydroxy-17-(2-methoxyacetyl)-13-methyl-1,2,6,7,8,11,12,13,14,15,16,17-dodecahydro-3h-cyclopenta[a]phenanthren-3-one
5. Unii-65703mv349
6. Telapristone [who-dd]
7. Schembl2168441
8. Dtxsid00173586
9. 11beta-(4-(dimethylamino)phenyl)-17-hydroxy-21-methoxy-19-norpregna-4,9-diene-3,20-dione
10. 19-norpregna-4,9-diene-3,20-dione, 17-hydroxy-11-(4-(dimethylamino)phenyl)-21-methoxy-, (11beta)-
11. Q27263837
12. (8s,11r,13s,14s,17r)-11-[4-(dimethylamino)phenyl]-17-hydroxy-17-(2-methoxyacetyl)-13-methyl-1,2,6,7,8,11,12,14,15,16-decahydrocyclopenta[a]phenanthren-3-one
13. 11.beta.-(4-(dimethylamino)phenyl)-17-hydroxy-21-methoxy-19-norpregna-4,9-diene-3,20-dione
14. 19-norpregna-4,9-diene-3,20-dione, 17-hydroxy-11-(4-(dimethylamino)phenyl)-21-methoxy-, (11.beta.)-
| Molecular Weight | 463.6 g/mol |
|---|---|
| Molecular Formula | C29H37NO4 |
| XLogP3 | 2.8 |
| Hydrogen Bond Donor Count | 1 |
| Hydrogen Bond Acceptor Count | 5 |
| Rotatable Bond Count | 5 |
| Exact Mass | 463.27225866 g/mol |
| Monoisotopic Mass | 463.27225866 g/mol |
| Topological Polar Surface Area | 66.8 Ų |
| Heavy Atom Count | 34 |
| Formal Charge | 0 |
| Complexity | 911 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 5 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 1 |
ABOUT THIS PAGE
A Telapristone manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Telapristone, including repackagers and relabelers. The FDA regulates Telapristone manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Telapristone API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
A Telapristone supplier is an individual or a company that provides Telapristone active pharmaceutical ingredient (API) or Telapristone finished formulations upon request. The Telapristone suppliers may include Telapristone API manufacturers, exporters, distributors and traders.
click here to find a list of Telapristone suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
A Telapristone DMF (Drug Master File) is a document detailing the whole manufacturing process of Telapristone active pharmaceutical ingredient (API) in detail. Different forms of Telapristone DMFs exist exist since differing nations have different regulations, such as Telapristone USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A Telapristone DMF submitted to regulatory agencies in the US is known as a USDMF. Telapristone USDMF includes data on Telapristone's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The Telapristone USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of Telapristone suppliers with USDMF on PharmaCompass.
Telapristone Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Telapristone GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Telapristone GMP manufacturer or Telapristone GMP API supplier for your needs.
A Telapristone CoA (Certificate of Analysis) is a formal document that attests to Telapristone's compliance with Telapristone specifications and serves as a tool for batch-level quality control.
Telapristone CoA mostly includes findings from lab analyses of a specific batch. For each Telapristone CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Telapristone may be tested according to a variety of international standards, such as European Pharmacopoeia (Telapristone EP), Telapristone JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Telapristone USP).
LOOKING FOR A SUPPLIER?
